Camurus AB (publ) (FRA:7CA)

Market Cap	3.78B +27.4%
Revenue (ttm)	212.93M +39.4%
Net Income	70.70M +193.6%
EPS	1.18 +189.5%
Shares Out	n/a
PE Ratio	53.45
Forward PE	33.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	81
Open	63.15
Previous Close	61.15
Day's Range	63.15 - 63.15
52-Week Range	45.66 - 67.80
Beta	n/a
RSI	57.57
Earnings Date	Feb 12, 2026

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocri...

• Industry: Pharmaceutical Preparations
• Founded: 1991
• Employees: 280
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7CA

Financial Performance

In 2024, Camurus AB's revenue was 1.87 billion, an increase of 8.78% compared to the previous year's 1.72 billion. Earnings were 428.39 million, a decrease of -0.71%.

Financial numbers in SEK